The paper discusses the identification of a novel negative allosteric modulator of the µ-opioid receptor (µOR) through screening with a DNA-encoded small molecule library.

Adzynma was approved by the U.S. Food and Drug Administration on November 9, 2023.

The US FDA extends approval for Jemperli (dostarlimab-gxly) combined with chemotherapy to all adults with advanced or recurrent endometrial cancer. It is the first immunotherapy showing overall survival benefits.

Ixchiq, the world's first chikungunya vaccine, was approved by the U.S. Food and Drug Administration on November 9, 2023.

Danuglipron is an oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. Pfizer plans to conduct dose-optimization studies in the second half of 2024.

Vamorolone, marketed under the brand name Agamree, was approved by the FDA on October 26, 2023.

Adaptimmune Gains FDA Accelerated Approval for TECELRA® (afamitresgene autoleucel), the First Engineered Cell Therapy for Solid Tumors in the U.S.

Cabtreo, a combination of clindamycin phosphate, adapalene, and benzoyl peroxide, was FDA-approved on October 20, 2023.

Eli Lilly currently holds the throne as the world's most valuable pharmaceutical company by market capitalization.

Sitagliptin is approved by the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes mellitus in adults. This approval was first granted on October 18, 2006.

ALX Oncology's Phase 2 ASPEN-06 Trial Shows Evorpacept Enhances Tumor Response in HER2-Positive Gastric Cancer Patients.

etrasimod (Velsipity) is FDA approved. The FDA granted its approval on October 12, 2023. This approval allows for the use of etrasimod in the treatment of adults with moderately to severely active ulcerative colitis.